NEW YORK (GenomeWeb) – MDxHealth today announced that Tufts Health Plan will provide its more than 1 million members with access to the firm's ConfirmMDx test for prostate cancer.

The agreement covers Tufts' government and commercial programs and products. Financial and other details were not disclosed.

ConfirmMDx for Prostate Cancer detects the methylation status of biomarkers associated with the cancer development process, identifying patients who many not need a repeat biopsy following a negative result.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.